MusclePharm (OTCMKTS:MSLP – Get Rating) and AbbVie (NYSE:ABBV – Get Rating) are both consumer staples companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.
Earnings and Valuation
This table compares MusclePharm and AbbVie's top-line revenue, earnings per share and valuation.
Get MusclePharm alerts:| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MusclePharm | $50.04 million | 0.00 | -$12.87 million | ($0.58) | 0.00 |
| AbbVie | $58.05 billion | 4.65 | $11.84 billion | $6.61 | 23.10 |
AbbVie has higher revenue and earnings than MusclePharm. MusclePharm is trading at a lower price-to-earnings ratio than AbbVie, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of current ratings and price targets for MusclePharm and AbbVie, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MusclePharm | 0 | 0 | 0 | 0 | N/A |
| AbbVie | 0 | 9 | 6 | 0 | 2.40 |
AbbVie has a consensus price target of $161.00, suggesting a potential upside of 5.43%. Given AbbVie's higher probable upside, analysts clearly believe AbbVie is more favorable than MusclePharm.
Profitability
This table compares MusclePharm and AbbVie's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MusclePharm | -38.51% | N/A | -169.56% |
| AbbVie | 20.39% | 154.52% | 17.54% |
Insider & Institutional Ownership
15.5% of MusclePharm shares are held by institutional investors. Comparatively, 67.7% of AbbVie shares are held by institutional investors. 60.7% of MusclePharm shares are held by insiders. Comparatively, 0.1% of AbbVie shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Volatility and Risk
MusclePharm has a beta of -0.07, indicating that its share price is 107% less volatile than the S&P 500. Comparatively, AbbVie has a beta of 0.61, indicating that its share price is 39% less volatile than the S&P 500.
Summary
AbbVie beats MusclePharm on 12 of the 13 factors compared between the two stocks.
About MusclePharm
(Get Rating)
MusclePharm Corporation develops, manufactures, markets, and distributes sports nutrition products and nutritional supplements in the United States and internationally. The company offers a range of performance powders, capsules, tablets, gels, and on-the-go ready to eat snacks. Its MusclePharm brand product portfolio includes combat protein powder and combat crunch protein bars; and essential supplements, such as a BCAA, creatine, glutamine, carnitine, CLA, fish oil, multi-vitamin, and other products. The company also provides FitMiss branded sports nutrition products, which are formulated primarily for the female body to support women in the areas of weight management, lean muscle mass, body composition, and general health and wellness; and functional energy beverages under the Combat Energy and FitMiss Energy brands. It sells its products to various athletes and fitness enthusiasts. The company was incorporated in 2006 and is based in Las Vegas, Nevada.
About AbbVie
(Get Rating)
AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
Receive News & Ratings for MusclePharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MusclePharm and related companies with MarketBeat.com's FREE daily email newsletter.